drugset / Trial / NCT05020925
SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
This is an open label, multi-center, phase I/II study to evaluate the efficacy and safety of SHR-1701 in combination with famitinib in subjects with recurrent/metastatic nasopharyngeal carcinoma(R/M NPC).
Timeline
- Start
- 2021-09
- Primary completion
- 2022-05
- Completion
- 2024-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Famitinib | Small molecule | — | Oral |
| Subject | Retlirafusp alfa | Protein / enzyme biologic | — | Intravenous |